Previous 10 | Next 10 |
3-part randomized, double-blind, placebo-controlled Phase 1 study will evaluate TRV045 safety, tolerability, and PK in healthy volunteers Enrollment expected to start in early Q1 2022 CHESTERBROOK, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a...
Trevena, Inc. (TRVN) Q3 2021 Earnings Conference Call November 15, 2021 08:00 ET Company Participants Barry Shin - Senior Vice President and Chief Financial Officer Carrie Bourdow - President and Chief Executive Officer Patty Drake - Chief Commercial Officer Bob Yoder - Chief Business Officer...
Trevena (NASDAQ:TRVN): Q3 GAAP EPS of -$0.08 beats by $0.01. Revenue of $0.18M (-94.0% Y/Y) misses by $0.53M. Press Release Cash and cash equivalents were $78.6M as of September 30, 2021, which the Company believes will be sufficient to fund the Company’s operating expenses and capital...
-- Advanced OLINVYK commercial launch with expanded field medical team and additional target markets Announced new OLINVYK cognitive function study vs. IV morphine, enrollment expected to start in Q1 2022 Initiated enrollment for Cleveland Clinic-led OLINVYK outc...
ACM, ACRX, ADN, AMPY, AVPT, AYRO, BCLI, BFLY, CLSN, OTCQB:CVSI, FREY, GMDA, GOED, KALA, MICT, OEG, ONDS, OTLY, PLX, PTN, RAIL, SOHU, TLS, TRVN, TSN, VBLT For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open
CHESTERBROOK, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the addition of Patricia Drake to...
CHESTERBROOK, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financia...
CHESTERBROOK, Pa., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two presentations at ANESTHESIOLO...
The last few weeks have started the same, and that’s with a list of penny stocks with potential catalysts. One of the exciting things about specific industries like biotech is that companies tend to pre-announce a date that news will come out in the future. Whether it’s someth...
-- 92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality ~12 days lower average hospital length of stay in patients treated with TRV027 compared to placebo ...
News, Short Squeeze, Breakout and More Instantly...
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones Trevena further expects a $10 million reduction in liabilities associated with its ex-US royalty financing ...
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in...